Align Technology (ALGN)
Builds Invisalign aligners, iTero scanners, and exocad software for digital dentistry.
Something off on this page? Send us feedback.
Sells doctor-prescribed Invisalign clear aligners and Vivera retainers, plus iTero intraoral scanners and exocad dental CAD/CAM software. Clear aligners generate most revenue, with scanners and software linking orthodontic and restorative workflows for dental practices and laboratories.
Designs, manufactures, and markets Invisalign clear aligners and Vivera retainers for orthodontists and general dentists. The Clear Aligner segment also includes Invisalign Palatal Expander and accessories, while the smaller Systems and Services segment sells iTero intraoral scanners and licenses exocad CAD/CAM software to dental practices and laboratories.
Connects digital scans, ClinCheck treatment planning, custom aligner fabrication, monitoring, and retention in a doctor-directed workflow. iTero and exocad extend that workflow into restorative dentistry. Sales span global markets, while manufacturing and treatment-planning operations are distributed across the Americas, Europe, and Asia.
Clear aligners generate most revenue. Demand depends on dental professionals prescribing the system and patients starting largely elective treatment, while products and software must meet medical-device, privacy, and data rules across markets.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 23, 2026 | UBS | Reiterate | Rating: —Target: $185 | Target: $189 |
| Jul 8, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $209 |
| Apr 24, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $154 | Target: $188 |
| Apr 21, 2026 | Piper Sandler | Reiterate | Rating: —Target: $220 | Target: $235 |
| Mar 17, 2026 | Barclays | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.10B · Total debt $120.8M · Total assets $6.42B · Shareholders' equity $4.23B
- Revenue
- $1.06B
- Operating income
- $123.3M
- Net income
- $108.3M
No dividends on record.
| Institutions | ≈ 106.47% | 75.64M shares | |
|---|---|---|---|
| 709 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 9.66% | 6.86M shares | |
| 19 holders · as of May 22, 2026 | |||
| Strategic holders | 2.01% | 1.43M shares | |
| 1 holder · as of Feb 11, 2021 | |||
| Adds to | 118.14% | ||
71.04M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.14%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Edgewood Management LLCInstitution | 6.49% | 4.61M | filed Feb 16, 2021 |
BlackRock, Inc.Institution | 6.22% | 4.42M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.20% | 4.40M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.72% | 4.06M | as of Jun 30, 2026 |
Capital International InvestorsInstitution | 5.69% | 4.05M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | John Morici | officer: EVP, CHIEF FINANCIAL OFFICER | −7,969 | $189.31 |
- Envista
Spark, Damon, and DEXIS pressure aligners, braces, and scanners
- Dentsply Sirona
SureSmile and Primescan overlap with aligners and digital scans
- Solventum
Clarity aligners and brackets contest orthodontic case starts
- Henry Schein
Smilers and orthodontic distribution overlap with doctor channels
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Align Technology | $153.43 | +0.03% | $10.52B | 25.5 | 13.0 | 2.5 | +4.3% |
| Envista | $24.18 | −0.02% | $3.81B | 40.4 | 15.4 | 1.3 | +7.1% |
| Dentsply Sirona | $9.98 | +0.30% | $1.89B | — | 6.8 | 0.5 | −4.1% |
| Solventum | $88.75 | −0.04% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Henry Schein | $87.43 | −0.04% | $9.71B | 24.8 | 15.5 | 0.7 | +6.7% |
| Median | 24.8 | 14.2 | 1.0 | +4.5% |